Scilex Holding (SCLX) Invested Capital (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Invested Capital of -$173.3 million for Q1 2026, down 0.72% year-over-year from -$174.6 million in Q1 2025, and down 39.17% on a QoQ basis from -$124.5 million in Q4 2025.
Scilex Holding (SCLX) Invested Capital (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Invested Capital for 7 consecutive years, with -$173.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Invested Capital fell 0.72% year-over-year to -$173.3 million; the TTM figure through Mar 2026 stood at -$173.3 million (down 0.72% YoY), while the FY2025 annual figure was -$124.5 million, up 21.07% from the prior year.
- Invested Capital came in at -$173.3 million for Q1 2026 at Scilex Holding, down from -$124.5 million in the prior quarter.
- The five-year high for Invested Capital was $36.2 million in Q4 2022, with the low at -$252.1 million in Q2 2022.
- Average Invested Capital over 5 years is -$122.5 million, with a median of -$131.3 million recorded in 2025.
- The largest YoY upside for Invested Capital was 123.87% in 2022 against a maximum downside of 2906.36% in 2022.
- Year by year, Invested Capital stood at $36.2 million in 2022, then slumped by 278.01% to -$64.5 million in 2023, then tumbled by 144.56% to -$157.8 million in 2024, then gained by 21.07% to -$124.5 million in 2025, then plunged by 39.17% to -$173.3 million in 2026.
- According to Business Quant data, Invested Capital over the past three periods registered -$173.3 million, -$124.5 million, and -$131.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 72.79 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 98.65 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -6.66 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 48.32 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 66.51 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 45.69 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 90.96 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -19.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -173.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -173.29 Mn |
| Dec 31, 2025 | -124.52 Mn |
| Sep 30, 2025 | -131.26 Mn |
| Jun 30, 2025 | -209.12 Mn |
| Mar 31, 2025 | -172.04 Mn |
| Dec 31, 2024 | -157.77 Mn |
| Sep 30, 2024 | -126.68 Mn |
| Jun 30, 2024 | -139.32 Mn |
| Mar 31, 2024 | -96.86 Mn |
| Dec 31, 2023 | -64.51 Mn |
| Sep 30, 2023 | -47.45 Mn |
| Jun 30, 2023 | 26.33 Mn |
| Mar 31, 2023 | 11.08 Mn |
| Dec 31, 2022 | 36.24 Mn |
| Sep 30, 2022 | -229.40 Mn |
| Jun 30, 2022 | -252.10 Mn |
| Mar 31, 2022 | -231.57 Mn |
| Dec 31, 2021 | -151.84 Mn |
| Sep 30, 2021 | -9.83 Mn |
| Jun 30, 2021 | -8.39 Mn |